The FDA granted Breakthrough Therapy Designation for nomlabofusp for adults and children with Friedreich's ataxia, and the FDA and company aligned on using skin FXN as a potential surrogate endpoint to support a planned BLA seeking accelerated approval in June 2026. Topline open-label study data to support the BLA are expected in Q2 2026, a global Phase 3 will be underway at submission, and a U.S. launch is targeted in H1 2027 if approved.
Cyborg Score Rationale
Larimar received FDA Breakthrough Therapy Designation for nomlabofusp for Friedreich's ataxia. Clinical data shows 100% of 10 participants achieving skin frataxin (FXN) >50% of healthy median at 6 months and a median mFARS improvement of 2.25 at 1 year versus a median worsening of 1.00 in a FACOMS reference population. However, the company continues to show ongoing net income losses of $132.0m with a negative return on equity of 94.94% and forecasts remaining unprofitable for at least the next 3 years.
Top Insights
FDA granted Breakthrough Therapy Designation to nomlabofusp, its frataxin protein replacement therapy candidate.
Company priced an underwritten public offering of 20 million common shares at $5.00 per share for $100 million gross proceeds, with offering expected to close on or about February 27, 2026.
FDA and company aligned on skin FXN as a surrogate endpoint for accelerated approval with topline data expected in Q2 2026 and U.S. launch targeted if approved.
Company plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Named Competitors
Protein replacement therapies — Developing treatments for rare genetic and mitochondrial disorders
Friedreich's ataxia treatments — Competing to address severe rare neurological disorder
Recent Developments
(February 2026) FDA granted Breakthrough Therapy Designation for nomlabofusp for Friedreich's ataxia, stock surged 31%
(February 2026) Closed $100 million underwritten public offering of common stock
(January 2026) Management presented at the 44th Annual J.P. Morgan Healthcare Conference
(September 2025) Announced positive clinical data and planned BLA submission timeline for Q2 2026
Open the full interactive Larimar Therapeutics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.